medigraphic.com
ISSN 0188-9796 (Print)

2002, Number 2

<< Back Next >>

Rev Endocrinol Nutr 2002; 10 (2)

Galectina 3 en el diagnóstico del cáncer folicular de tiroides

Pérez EB, Rivera MR

Language: Spanish
References: 17
Page: 89-93
PDF size: 146.54 Kb.


ABSTRACT

Galectin-3 is a lectin with intracellular and extracellular functions. Galectin-3 is upregulated in thyroid follicular neoplasms and the immunohistochemical localization in follicular cells provides a good cytological marker for preoperative diagnosis of thyroid follicular carcinoma in nodular lesions.


REFERENCES

  1. Barondes SH, Cooper DNW, Gitt MA, Leffler H. Galectins:structure and function of a large family of lectins. J BiolChem 1994; 269: 20807-10.

  2. Cooper DNW, Barondes SH. 1999. God must love galectins;he made so many of them. Glycobiology 1999; 9: 979-84.

  3. Yang R-Y, Hsu DK, Yu L, Ni J, Liu F-T. Cell cycle regulation bygalectin-12, a new member of the galectin superfamily. JBiol Chem 2001; 276: 20252-60.

  4. Sano H, Hsu DK, Yu L et al. Human galectin-3 is a novelchemoattractant for monocytes and macrophages. JImmunol 2000; 165: 2156-64.

  5. Kawachi K, Matsushita Y, Yonezawa S et al. Galectin-3expression in various thyroid neoplasms and its possible rolein metastasis formation. Hum Pathol 2000; 31: 428-33.

  6. Raber W, Kaserer K, Niederle B, Vierhapper H. Risk factorsfor malignancy of thyroid nodules initially identified asfollicular neoplasia by fine-needle aspiration: results of aprospective study of one hundred twenty patients. Thyroid2000; 10: 709-12.

  7. Schlinkert RT, van Heerden JA, Goellner JR et al. Factorsthat predict malignant thyroid lesions when fine-needleaspiration is “suspicious for follicular neoplasm”. Mayo ClinProc. 1997; 72: 913-6.

  8. Xu XC, Nl-Naggar AK, Lotan R. Differential expression ofgalectin-1 and galectin-3 in thyroid tumors: potentialdiagnostic implications. Am J Pathol 1995; 147: 815-22.

  9. Fernández PL, Merino MJ, Gómez M et al. Galectin-3 andlaminin expression in neoplastic and non-neoplastic thyroidtissue. J Pathol 1997; 181: 80-6.

  10. Orlandi F, Saggiorato E, Pivano G et al. Galectin-3 is apresurgical marker of human thyroid carcinoma. Cancer Res1998; 58: 3015-20.

  11. Cvejic D, Savin S, Paunovic I et al. Immunohistochemicallocalization of galectin-3 in malignant and benign humanthyroid tissue. Anticancer Res 1998; 18: 2637-41.

  12. Inohara H, Honjo Y, Yoshii T et al. Expression of galectin-3in fine-needle aspirates as a diagnostic marker differentiatingbenign from malignant thyroid neoplasms. Cancer1999; 85: 2475-84.

  13. Nascimento MC, Bisi H, Alves VA et al. Differential reactivityfor galectin-3 in Hürthle cell adenoma and carcinomas.Endocr Pathol 2001; 12: 275-9.

  14. Saggiorato E, Cappia S, de Giuli P. Galectin-3 as apresurgical immunocytodiagnostic marker of minimallyinvasive follicular thyroid carcinoma. J Clin Endocrinol Metab2001; 86: 5152-8.

  15. Mizukami Y, Nonomura A, Hayashi Y et al. Late bonemetastasis from an encapsulated follicular carcinoma of thethyroid without capsular and vascular invasion. Pathol Int1996; 46: 457-61.

  16. Hirai K, Kotani T, Aratake Y, Ohtaki S, Kuma K. Dipeptidylpeptidase IV (DPP IV/CD26) staining predicts distantmetastasis of “benign” thyroid tumor. Pathol Int 1999; 49:264-5.

  17. Bartolazzi A, Gasberri A, Papotti M et al. Application of animmunodiagnostic method for improving preoperative diagnosisof nodular thyroid lesions. Lancet 2001; 357: 1644-50.




2020     |     www.medigraphic.com